AU1067695A - Use of lithium compounds in the treatment of cardiac insufficiency - Google Patents

Use of lithium compounds in the treatment of cardiac insufficiency

Info

Publication number
AU1067695A
AU1067695A AU10676/95A AU1067695A AU1067695A AU 1067695 A AU1067695 A AU 1067695A AU 10676/95 A AU10676/95 A AU 10676/95A AU 1067695 A AU1067695 A AU 1067695A AU 1067695 A AU1067695 A AU 1067695A
Authority
AU
Australia
Prior art keywords
treatment
lithium compounds
cardiac insufficiency
sequelae
angiotensin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU10676/95A
Inventor
Karla Lehmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU1067695A publication Critical patent/AU1067695A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to the use of lithium compounds alone or in combination with ACE inhibitors and/or receptor antagonists of angiotensin II in the treatment of cardiac insufficiency including its sequelae, with a view in particular to reducing the mortality due to the associated cardiovascular disorders.
AU10676/95A 1993-11-27 1994-11-26 Use of lithium compounds in the treatment of cardiac insufficiency Abandoned AU1067695A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4340437A DE4340437C1 (en) 1993-11-27 1993-11-27 Use of lithium compounds for the treatment of heart failure including its complications
DE4340437 1993-11-27
PCT/EP1994/003920 WO1995014490A1 (en) 1993-11-27 1994-11-26 Use of lithium compounds in the treatment of cardiac insufficiency

Publications (1)

Publication Number Publication Date
AU1067695A true AU1067695A (en) 1995-06-13

Family

ID=6503584

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10676/95A Abandoned AU1067695A (en) 1993-11-27 1994-11-26 Use of lithium compounds in the treatment of cardiac insufficiency

Country Status (5)

Country Link
EP (1) EP0730471B1 (en)
AT (1) ATE200983T1 (en)
AU (1) AU1067695A (en)
DE (2) DE4340437C1 (en)
WO (1) WO1995014490A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19530319A1 (en) * 1995-08-17 1997-02-20 Woerwag Pharma Gmbh Use of orotic acid to treat patients indicated for heart transplantation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
BR9106438A (en) * 1990-05-11 1993-05-18 Pfizer SYNERGISTIC THERAPEUTIC COMPOSITIONS AND PROCESSES

Also Published As

Publication number Publication date
ATE200983T1 (en) 2001-05-15
DE59409746D1 (en) 2001-06-13
WO1995014490A1 (en) 1995-06-01
DE4340437C1 (en) 1995-05-24
EP0730471B1 (en) 2001-05-09
EP0730471A1 (en) 1996-09-11

Similar Documents

Publication Publication Date Title
EG18081A (en) Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as the use indurugs
BR9915134A (en) Co-therapy and combination therapy for the treatment of cardiovascular disorders in an individual, and composition
CA2251331A1 (en) Calcilytic compounds
IS4394A (en) Therapeutic compounds, pharmaceutically acceptable salts and compositions containing the compounds, together with their use
YU53899A (en) Use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing cardiovascular disorders
MY110205A (en) Imidazolyl-alkenoic acids.
MY138239A (en) Nitrogen containing heterobicycles as factor xa inhibitors
EP0912174A4 (en) Alteration of circadian rhythmicity with a tachykinin antagonist
ES2167571T3 (en) ANTIGONIST COMBINATION THERAPY OF ALDOSTERONE EPOXY-STEROID AND ANGIOTENSIN II ANTAGONIST FOR THE TREATMENT OF CONGESTIVE CARDIAC FAILURE.
ZA941525B (en) Use of riluzole in the treatment of nero-AIDS
ZA857932B (en) Combination of dihydropyridines with ace inhibitors and their use in medicaments
AU9064991A (en) Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathy
ZA943690B (en) Imidazole 5-position substituted angiotensin II antagonists
AU3745795A (en) Use of CCK-B receptor antagonists for the treatment of sleepdisorders
AU9052991A (en) Use of angiotensin ii antagonist in the treatment of infarction
EP1262175A3 (en) Use of renin-angiotensin antagonist for reducing post myocardial infarct mobidity and mortality
EA200100951A1 (en) COMBINED THERAPY WITH INHIBITOR ANGIOTENZIN-CONVERTING ENZYME AND EPOXYSTROID ANTAGONIST ALDOSTERONE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
EP0635263A3 (en) Angiotensin (AII) antagonists as inhibitors of the growth of adipose tissue.
AU9081691A (en) Use of angiotensin ii antagonists in the treatment of angina pectoris
CA2055948A1 (en) Use of a combination of angiotensin-converting enzyme inhibitor and calcium antagonist for the treatment of proteinuria
AU1067695A (en) Use of lithium compounds in the treatment of cardiac insufficiency
NO20013459D0 (en) Use of agiotensin II receptor antagonists in the treatment of acute myocardial infarction
EP1136078A3 (en) Combination of angiotensin converting enzyme inhibitor and side- effect-reduced amount of aldosterone antagonist
AU9071291A (en) Use of angiotensin ii antagonists in the treatment of left ventricular hypertrophy
MX9707939A (en) Use of leukemia inhibitory factor and endothelin antagonists.